Triple chemo cocktail shows promise against tough pancreatic cancer

NCT ID NCT03915444

Completed Disease control Sponsor: HonorHealth Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested a combination of three chemotherapy drugs (nab-paclitaxel, cisplatin, and gemcitabine) in 42 people with metastatic pancreatic cancer that had not been treated before. The main goal was to see how many patients were alive after 12 months. The study also tracked side effects and tumor shrinkage. Results suggest this combo may improve survival, but larger studies are needed to confirm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nab-paclitaxel, cisplatin, and gemcitabine (three chemotherapy drugs given together)
What this could lead to: If successful, this combination could offer a new treatment option to help people with metastatic pancreatic cancer live longer.
What could go wrong: This is a small, early-phase trial (42 people) without a comparison group. The results may not apply to everyone, and the drugs can cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

Froedtert & Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
HonorHealth Research Institute

Scottsdale, Arizona, 85258, United States
Ochsner Clinic Foundation

New Orleans, Louisiana, 70121, United States
University of Miami

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.